HBM-1022

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameHBM-1022
Drug Alias NameHBM-1022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHarbour Biomed
China Registration ClassN/A

Develop Information

Active CompaniesHarbour Biomed
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A